Street Capital Stock Price

CNSX:STRC.XCA$1.4mPharmaceuticals & Biotech

STRC.X Share Price Performance

STRC.X Community Fair Values

RenovoRx
ST
Stock_Research_Today
Community Contributor
Revolutionizing Cancer Treatment
A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.
View narrative
US$4.20
FV
66.2% undervalued intrinsic discount
371.30%
Revenue growth p.a.
11users have liked this narrative
0users have commented on this narrative
107users have followed this narrative
about 1 month ago author updated this narrative
Your Fair Value
CA$
Current Price
CA$0.00570.6% undervalued intrinsic discount
Growth estimate over
Annual revenue growth rate
%/yr
Decrease
Increase
Advanced

View all narratives

Recent STRC.X News & Updates

Street Capital Inc. Competitors

View more competitors

Street Capital Inc. Key Details

Last Reported Earnings

Sep 30, 2024

Yearly revenue growth

n/a

Earnings per share (EPS): -0.00078
Gross Margin: 51.34%
Net Profit Margin: -50.80%
Debt/Equity Ratio: -49.4%

View full report ›

Canadian Market Performance

7 Days: 1.0%
3 Months: 7.9%
1 Year: 15.8%
Year to Date: 6.1%

The market has climbed 1.0% in the last 7 days, lead by the Materials sector with a gain of 3.7%. In contrast, the Healthcare sector is lagging, dropping 3.1%. In the last year, the market has climbed 16%. Looking forward, earnings are forecast to grow by 12% annually. Market details ›

🤖 A.I. Enters the “Show Me The Money” Phase

Richard Bowman

May 2025

The AI frenzy of 2023 and 2024 has cooled down and entered the "show me the money" phase. Earnings season has shed a lot of light on where we stand. So it’s time for an update on the industry and a look at the companies successfully deploying AI, monetizing it, and the potential opportunities for investors.

Last Week

Street Capital Stock Price

STRC.X Share Price Performance

STRC.X Community Fair Values

Revolutionizing Cancer Treatment

Recent STRC.X News & Updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Third quarter 2024 earnings released: EPS: CA$0 (vs CA$0 in 3Q 2023)

Insufficient new directors

Insufficient new directors

Insufficient new directors

New major risk - Financial position

Street Capital Inc. Competitors

🤖 A.I. Enters the “Show Me The Money” Phase

🧬 The Convergence of Genomic Medicine and AI Drug Discovery